Piper Sandler Starts Benitec at Overweight, Cites BB-301 Opportunity
Benitec Biopharma Initiated at Overweight by Piper Sandler
Benitec Biopharma Initiated at Overweight by Piper Sandler
Piper Sandler Initiates Benitec Biopharma(BNTC.US) With Buy Rating, Announces Target Price $30
Piper Sandler analyst Yasmeen Rahimi initiates coverage on $Benitec Biopharma(BNTC.US)$ with a buy rating, and sets the target price at $30.According to TipRanks data, the analyst has a success rate o
Express News | Piper Sandler Initiates Coverage On Benitec Biopharma With Overweight Rating, Announces Price Target of $30
FFIE, OGEN and CCLD Among Mid-day Movers
12 Health Care Stocks Moving In Monday's Intraday Session
GainersCareCloud (NASDAQ:CCLD) stock moved upwards by 80.5% to $2.27 during Monday's regular session. The company's market cap stands at $36.6 million. Novavax (NASDAQ:NVAX) stock rose 42.17% to $12.6
Express News | Benitec Biopharma Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 GAAP EPS Results and a Year-over-year Decrease in Q3 Revenue Results
Express News | Benitec Biopharma Q3 2024 Revenue $0 Down From $54,000 YoY
Express News | Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
Express News | Benitec Biopharma Q3 Net Income USD -4.3 Million
Express News | Benitec Biopharma Q3 EPS USD -1.64
Express News | Benitec Biopharma Inc - Closed an Oversubscribed Private Placement Financing of $40.0 Million on April 22Nd, Cash Runway Extended Through 2025
Express News | Benitec Biopharma Inc - Qtrly Shr Loss $1.64
Benitec Biopharma | 10-Q: Quarterly report
Global RNAi Therapeutics Market Insights & Forecasts With Potential Impact of COVID-19 2024-2028 Featuring Sanofi, Alnylam, Arrowhead, Arbutus Biopharma, Benitec Biopharma, Sirnaomics - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been add
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference
HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel g
Express News | Suvretta Capital Management LLC Reports a Stake of 19.99% in Benitec Biopharma as of April 22, 2024
Express News | Benitec Biopharma 13G Filing Shows Steven Oliveira Reported A 8.89% Passive Stake In The Co As Of April 22
Express News | Steven Oliveira Reports 8.89% Passive Stake in Benitec Biopharma Inc as of April 22 - SEC Filing
JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $16
JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma with a Market Outperform and raises the price target from $10 to $16.
No Data